目的评价89Sr和云克(99Tc-MDP)联合治疗骨转移癌的临床疗效。方法对46例骨转移癌患者采用89Sr和云克(99Tc-MDP)联合治疗,对治疗后的止痛效果、不良反应进行观察、随访。结果治疗骨痛显效24%,有效54.3%,无效21.7%,总有效率78.3%。临床可见白细胞轻度降低,可恢复正常,未见其他严重不良反应。结论89Sr和云克(99Tc-MDP)联合治疗骨转移癌是安全有效的。 Objective To evaluate the clinical efficacy of 89Sr and 99Tc-MDP in the treatment of bone metastases. Methods Forty-nine patients with bone metastatic carcinoma were treated with 89Sr and 99Tc-MDP. The analgesic effect and adverse reactions after treatment were observed and followed up. Results The treatment effect of bone pain was 24%, effective 54.3%, invalid 21.7%, and total effective rate 78.3%. It is clinically seen that the white blood cells are slightly reduced and can return to normal without any other serious adverse reactions. Conclusion 89Sr and 99Tc-MDP are safe and effective in the treatment of bone metastases.